Business Description
![MorphoSys AG MorphoSys AG logo](https://static.gurufocus.com/logos/0C00000UDR.png?14)
MorphoSys AG
ISIN : US6177602025
Share Class Description:
MOR: ADRCompare
Compare
Traded in other countries / regions
MOR.GermanyMOR.USA0NDV.UKMOR.Austria1MOR.ItalyMOR.Switzerland IPO Date
2018-04-19Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.07 | |||||
Equity-to-Asset | 0.02 | |||||
Debt-to-Equity | 12.97 | |||||
Debt-to-EBITDA | -12.44 | |||||
Altman Z-Score | 0.42 | |||||
Beneish M-Score | -3.19 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.1 | |||||
3-Year FCF Growth Rate | -173.8 | |||||
3-Year Book Growth Rate | -59 | |||||
Future 3-5Y EPS without NRI Growth Rate | 41.15 | |||||
Future 3-5Y Total Revenue Growth Rate | 23.9 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 75.22 | |||||
9-Day RSI | 64.99 | |||||
14-Day RSI | 60.22 | |||||
6-1 Month Momentum % | 63.5 | |||||
12-1 Month Momentum % | 139.42 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.08 | |||||
Quick Ratio | 2.84 | |||||
Cash Ratio | 2.58 | |||||
Days Inventory | 301.86 | |||||
Days Sales Outstanding | 98.58 | |||||
Days Payable | 524.66 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.7 | |||||
Shareholder Yield % | 2.11 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.48 | |||||
Operating Margin % | -105.22 | |||||
Net Margin % | -79.6 | |||||
FCF Margin % | -83.05 | |||||
ROE % | -226.44 | |||||
ROA % | -8.63 | |||||
ROIC % | -17.83 | |||||
ROC (Joel Greenblatt) % | -139.64 | |||||
ROCE % | -2.94 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.68 | |||||
PB Ratio | 51.57 | |||||
EV-to-EBIT | -43.71 | |||||
EV-to-EBITDA | -48.63 | |||||
EV-to-Revenue | 10.43 | |||||
EV-to-FCF | -12.57 | |||||
Price-to-Median-PS-Value | 0.47 | |||||
Earnings Yield (Greenblatt) % | -2.29 | |||||
FCF Yield % | -7.81 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MOR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MorphoSys AG Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 256.837 | ||
EPS (TTM) ($) | -1.474 | ||
Beta | 1.48 | ||
Volatility % | 81.63 | ||
14-Day RSI | 60.22 | ||
14-Day ATR ($) | 0.350525 | ||
20-Day SMA ($) | 18.5835 | ||
12-1 Month Momentum % | 139.42 | ||
52-Week Range ($) | 4.185 - 19.5 | ||
Shares Outstanding (Mil) | 150.65 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 0 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
MorphoSys AG Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
MorphoSys AG Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
MorphoSys AG Frequently Asked Questions
What is MorphoSys AG(MOR)'s stock price today?
The current price of MOR is $18.96. The 52 week high of MOR is $19.50 and 52 week low is $4.18.
When is next earnings date of MorphoSys AG(MOR)?
The next earnings date of MorphoSys AG(MOR) is 2024-11-15 Est..
Does MorphoSys AG(MOR) pay dividends? If so, how much?
MorphoSys AG(MOR) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |